

# Plasmapheresis

[View the current Plasmapheresis InDepth page on BioPortfolio.com](http://www.bioportfolio.com/indepth/Plasmapheresis.html)

(<http://www.bioportfolio.com/indepth/Plasmapheresis.html>)

Plasmapheresis is the removal, treatment, and return of blood plasma from blood circulation. It is thus an extracorporeal therapy. The method can also be used to collect plasma for further manufacturing into a variety of medications.

## Recent Publications on Plasmapheresis:



- [Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report.](#)  
*PURPOSE:* The purpose of this report is to describe the management and...1st January, 2009  
Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton- Cancer Chemother Pharmacol. 2008 Dec 31. ([DOI Direct Link](#))
- [The diagnostic dilemma of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the obstetric triage and emergency department: lessons from 4 tertiary hospitals.](#)  
*OBJECTIVE:* We report a series of occurrences of thrombotic...27th December, 2008  
University of Cincinnati College of Medicine, Department of Obstetrics &- Am J Obstet Gynecol. 2008 Dec 24. ([DOI Direct Link](#))
- [\[Respiratory involvement in systemic lupus erythematosus.\]](#)  
*Respiratory involvement in systemic lupus erythematosus (SLE) is not as...*25th December, 2008  
Service de Pneumologie, CHRU et Universite Francois Rabelais de Tours,- Rev Mal Respir. 2008 Dec;25(10):1289-303. ([DOI Direct Link](#))
- [An alternate explanation for the decrease in pemphigus antibodies with combination treatment of double-filtration plasmapheresis and IVIg.](#)  
*Respiratory involvement in systemic lupus erythematosus (SLE) is not as...*25th December, 2008  
- Eur J Dermatol. 2008 Dec 23. ([DOI Direct Link](#))
- [\[Anesthetic maintenance of renal transplantation in children\]](#)  
*For many children with severe renal excretory dysfunction, renal...*24th December, 2008  
- Anesteziol Reanimatol. 2008 Sep-Oct;(5):58-61.
- [C4d-positive interacinar capillaries correlates with donor-specific antibody-mediated rejection in pancreas allografts.](#)  
*BACKGROUND:* The deposition of the complement split fragment C4d and its...24th December, 2008  
Department of Pathology and Laboratory Medicine, University of- Transplantation. 2008 Dec 27;86(12):1849-56. ([DOI Direct Link](#))
- [ABO Blood Type Incompatible Kidney Transplantation Without Splenectomy Prepared With Plasma Exchange and Rituximab.](#)  
*We have designed a protocol for ABO-incompatible kidney transplantations...*23rd December, 2008  
Department of Urology, St. Marianna University, Kawasaki, Kanagawa, Japan.- Transplant Proc. 2008

- Dec;40(10):3445-7. ([DOI Direct Link](#))
- [High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis.](#)  
*Antibody-mediated rejection (AMR) generally occurs in highly sensitized...*23rd December, 2008  
Dallas Nephrology Associates, Dallas, Texas, USA.- Transplant Proc. 2008 Dec;40(10):3393-6. ([DOI Direct Link](#))
  - [Athrombocytopenic thrombotic microangiopathy, a condition that could be overlooked based on current diagnostic criteria.](#)  
*BACKGROUND: Thrombotic thrombocytopenic purpura (TTP) and haemolytic...*20th December, 2008  
The Nephrology Research Group, L'Hotel-Dieu de Quebec Research- Nephrol Dial Transplant. 2008 Dec 18. ([DOI Direct Link](#))
  - [Successful Treatment of Cardiogenic Shock Caused by Humoral Cardiac Allograft Rejection.](#)  
*The progress of immunosuppressive therapy has made heart transplantation...*18th December, 2008  
Division of Cardiovascular Surgery, Department of Surgery, Osaka- Circ J. 2008 Dec 16.
  - [Role of basic studies in expanding the donor pool for liver transplantation.](#)  
*BACKGROUND: Liver transplantation is an effective treatment for end-stage...*17th December, 2008  
Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public- Hepatobiliary Pancreat Dis Int. 2008 Dec;7(6):571-80.
  - [Hypersensitivity to plasma exchange in a patient with thrombotic thrombocytopenic purpura.](#)  
*To a limited extent, thrombotic thrombocytopenic purpura (TTP) in addition...*17th December, 2008  
Department of Medicine, New York Medical College, Valhalla, New York.- J Clin Apher. 2008 Dec 15. ([DOI Direct Link](#))
  - [\[Treatment of post-transplant glomerulonephritis.\]](#)  
*The treatment of recurrent glomerulonephritis (GN) is often empirical....*17th December, 2008  
Divisione di Nefrologia, A.O. Spedali Civili, Brescia - Italy.- G Ital Nefrol. 2008 Nov-Dec;25 Suppl 44:99-106.
  - [Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12 months: follow-up of immunopathological and clinical effects.](#)  
*Systemic sclerosis (SSc) is an autoimmune disease which involves the skin,...*11th December, 2008  
Department of Rheumatology, University of Debrecen Medical Center, 22- Clin Rheumatol. 2008 Dec 6. ([DOI Direct Link](#))
  - [\[Up-to-date technologies in preoperative preparation and postoperative period in patients with progressive destructive pulmonary tuberculosis\]](#)  
*The impact of complex pathogenetic treatment involving the latest advances...*10th December, 2008  
- Probl Tuberk Bolezn Legk. 2008;(9):25-8.

## Plasmapheresis Clinical Trials:



- [Study to Evaluate the Amount of Medications That May be Removed From the Body During Plasmapheresis](#)



## Plasmapheresis Patents:

- 7326571- [Decellularized bone marrow extracellular matrix](#)
- 7358058- [Method and agents for the diagnosis and therapy of chronic inflammatory intestinal disease](#)
- 7361739- [Methods and apparatus for creating particle derivatives of HDL with reduced lipid content](#)
- 7361748- [von Willebrand factor \(vWF\)--cleaving protease](#)
- 7364658- [Systems and methods using multiple solvents for removal of lipids from fluids](#)
- 7368438- [Non-nucleotide compositions and method for inhibiting platelet aggregation](#)
- 7374678- [Apparatus and method for separating and concentrating fluids containing multiple components](#)
- 7374791- [Method for making and measuring a coating on the surface of a medical device using an ultraviolet laser](#)
- 7375191- [Methods and apparatus for creating particle derivatives of HDL with reduced lipid content](#)
- 7388051- [Propylene polymer composition and use thereof](#)
- 7393337- [Method of monitoring the operability of a flow cut-off member and flow arresting system, for an extracorporeal fluid circuit](#)
- 7357916- [Method for creating a uniform vascular wound in zebrafish or zebrafish larva](#)
- 7355017- [Blood group antigen fusion polypeptides and methods of use thereof](#)
- 7354392- [Structurally optimized hollow fiber membranes](#)
- 7329739- [Use of lectin library for distinguishing glycoproteins or cells, diagnosing serum or cells, or fractionating glycoproteins or cells](#)
- 7332168- [Composition for the elimination of autoreactive B-cells](#)
- 7335648- [Non-nucleotide composition and method for inhibiting platelet aggregation](#)
- 7335681- [Amino ceramide-like compounds and therapeutic methods of use](#)
- 7341843- [Botulinum toxin A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy](#)
- 7342013- [Benzamides and related inhibitors of factor Xa](#)
- 7342115- [3-substituted-6-aryl pyridines](#)
- 7344715- [Method for treating multiple myeloma](#)
- 7345047- [Substituted \[1,2,3\]triazolo\[4,5-d\]pyrimidines](#)
- 7348176- [Chamber with adjustable volume for cell culture and organ assist](#)
- 7393826- [Methods and apparatus for creating particle derivatives of HDL with reduced lipid content](#)
- 7396859- [Perturbed membrane-binding compounds](#)
- 7442303- [Microporous filter membrane, method of making microporous filter membrane and separator employing microporous filter membranes](#)
- 7449177- [Remedy for pemphigoid](#)
- 7449314- [Rapid thermal cycle processing methods and apparatus](#)
- 7449557- [Complexes of alpha \(2\) macroglobulin and antigenic molecules for immunotherapy](#)
- 7452870- [Drug-eluting stents coated with P2Y.sub.12 receptor antagonist compound](#)
- 7455771- [Means for removing protein-bound substances](#)
- 7459169- [Surface coating comprising bioactive compound](#)
- 7462699- [BoNT/A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy](#)
- 7468258- [Self-quenching homofluorophore compositions for detecting enzyme activity](#)
- 7470245- [Extracorporeal pathogen reduction system](#)
- 7439052- [Method of making modified immunodeficiency virus particles](#)

- 7438714- [Vacuum-based catheter stabilizer](#)
- 7435724- [Degradation-resistant mononucleoside phosphate compounds](#)
- 7402246- [Systems and methods using multiple solvents for the removal of lipids from fluids](#)
- 7404951- [Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels](#)
- 7407662- [Modified viral particles with immunogenic properties and reduced lipid content](#)
- 7407663- [Modified immunodeficiency virus particles](#)
- 7410642- [Assays and therapies for latent viral infection](#)
- 7417039- [Use of substituted azetidinone compounds for the treatment of sitosterolemia](#)
- 7419683- [Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules](#)
- 7422565- [Support element for an extracorporeal fluid transport line](#)
- 7424821- [Characterization of porous media](#)
- 7435235- [Blood treatment equipment, method, and software program for controlling infusion in blood treatment equipment](#)
- 7470371- [Methods and apparatus for isolating platelets from blood](#)

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

